Therefore, we hypothesize that patients with high CXCL10 and high CXCL13 define a subset of RA whose inflammatory reactions are primarily driven by TNF and thus respond to TNF inhibitor therapy. This evidence concerns the gene TNF and rheumatoid arthritis.